The
Food and Drug Administration granted Breakthrough Therapy Designation
to Celldex Therapeutics Inc.'s (Nasdaq: CLDX) adult patients with
EGFRvIII-positive glioblastoma treatment rindopepimut. Shares of the biopharmaceutical leaped $3.52 to close at $24.73.
Celldex receives Breakthrough Therapy Designation
February 23, 2015 at 15:54 PM EST